Literature DB >> 18627238

Cryptosporidiosis in 20 alpaca crias.

Laura H Waitt1, Christopher K Cebra, Anna M Firshman, Erica C McKenzie, John W Schlipf.   

Abstract

CASE DESCRIPTION: 20 alpaca crias (13 females and 7 males) were examined for diarrhea (n=20), weight loss (15), and poor appetite (5). Fourteen crias were between 8 and 18 days of age at time of admission. CLINICAL
FINDINGS: Cryptosporidiosis was diagnosed in all crias. Common biochemical abnormalities included acidemia, hyperlactemia, azotemia, and hyperglycemia and increases in aspartate transaminase and gamma-glutamyltransferase activities. Serum sodium and chloride concentrations were high or low. Other potential gastrointestinal tract pathogens were identified in only 7 crias. TREATMENT AND OUTCOME: Supportive care was instituted, including i.v. administration of fluids with partial parenteral administration of nutrients (n=19 crias), antimicrobials (19), supplemental orally administered nutrients (11), administration of plasma (10), and insulin treatment (9). Other palliative treatments used by attending clinicians were sucralfate, flunixin meglumine, vitamin A/D/E/B complex, antiparasitic agents, antidiarrheal agents, and azithromycin. Three crias with inadequate urine production and severe azotemia were treated with furosemide administered i.v. as a bolus or as a constant-rate infusion. Treatment resulted in a successful outcome in 16 of 20 crias. Weight loss and refractory azotemia were common in nonsurvivors but not in surviving crias. CLINICAL RELEVANCE: Findings suggested that Cryptosporidium spp may be a diarrheal pathogen of unweaned alpaca crias that may be more widespread than has been recognized and can become endemic on some farms. Metabolic derangements were unpredictable and should be determined by biochemical analysis before fluid and electrolyte replacement is initiated. Cryptosporidiosis has zoonotic potential, and the infection can be self-limiting in alpacas receiving supportive treatment.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18627238     DOI: 10.2460/javma.233.2.294

Source DB:  PubMed          Journal:  J Am Vet Med Assoc        ISSN: 0003-1488            Impact factor:   1.936


  7 in total

1.  Retrospective evaluation of parenteral nutrition in alpacas: 22 cases (2002-2008).

Authors:  E R S Clore; L M Freeman; D Bedenice; C A Tony Buffington; D E Anderson
Journal:  J Vet Intern Med       Date:  2011-03-21       Impact factor: 3.333

2.  Cryptosporidium parvum as a risk factor of diarrhea occurrence in neonatal alpacas in Peru.

Authors:  Luis A Gomez-Puerta; Armando E Gonzalez; Ana Vargas-Calla; Maria T Lopez-Urbina; Vitaliano Cama; Lihua Xiao
Journal:  Parasitol Res       Date:  2019-11-22       Impact factor: 2.289

3.  Molecular identification of Cryptosporidium spp. in alpacas (Vicugna pacos) in China.

Authors:  Qiyuan Zhang; Junqiang Li; Zhiguo Li; Chunyan Xu; Minyu Hou; Meng Qi
Journal:  Int J Parasitol Parasites Wildl       Date:  2020-06-20       Impact factor: 2.674

4.  Presence and molecular characterisation of Giardia and Cryptosporidium in alpacas (Vicugna pacos) from Peru.

Authors:  Hipólito Gómez-Couso; Luis M Ortega-Mora; Adriana Aguado-Martínez; Raúl Rosadio-Alcántara; Lenin Maturrano-Hernández; Luis Luna-Espinoza; Víctor Zanabria-Huisa; Susana Pedraza-Díaz
Journal:  Vet Parasitol       Date:  2012-01-28       Impact factor: 2.738

5.  Clinical findings and survival in 56 sick neonatal New World camelids.

Authors:  F R Bertin; J M Squires; J E Kritchevsky; S D Taylor
Journal:  J Vet Intern Med       Date:  2014-10-15       Impact factor: 3.333

6.  First cross-sectional, molecular epidemiological survey of Cryptosporidium, Giardia and Enterocytozoon in alpaca (Vicugna pacos) in Australia.

Authors:  Anson V Koehler; Mohammed H Rashid; Yan Zhang; Jane L Vaughan; Robin B Gasser; Abdul Jabbar
Journal:  Parasit Vectors       Date:  2018-09-05       Impact factor: 3.876

7.  Neonatal diseases in llamas and alpacas.

Authors:  Claire E Whitehead
Journal:  Vet Clin North Am Food Anim Pract       Date:  2009-07       Impact factor: 3.357

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.